Opko Health, Inc.

Good afternoon, ladies and gentlemen, and welcome to the Opco Health Second Quarter 2021 Financial Results Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session, and instructions will follow at that time. If anyone should require assistance during the conference, please press 0 on your touch-tone telephone. As a reminder, this conference call is being recorded. I would now like to turn the conference over to your host, Ms. Yvonne Briggs of LHA. Ma'am, please go ahead.

Thank you, operator. Good afternoon. This is Yvonne Briggs with LHA. Thank you all for joining today's call to discuss Opco Health's financial results for the second quarter of 2021. I'd like to remind you that any statements made during this call by management other than statements of historical fact will be considered forward-looking and as such will be subject to risks and uncertainties that could materially affect the company's expected results. Those forward-looking statements include, without limitation, the various risks described in the company's SEC filings, including the annual report on Form 10-K for the year ended December 31, 2020, and in subsequently filed SEC reports. Importantly, this conference call contains time-sensitive information that is accurate only as of the date of the live broadcast, today, July 29, 2021. Except as required by law, OPCO undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this call. Before we begin, let me review the format for today's call. Dr. Philip Frost, Chairman and Chief Executive Officer, will open the call. Steve Rubin, OPCO's Executive Vice President, will provide a business update and pipeline review, and then Dr. John Cohen will discuss bioreference laboratories. After that, Adam Logel, OPCO's CFO, will review the company's second quarter financial results, and then we'll open up the call to questions. Now I'd like to turn the call over to Dr. Frost.

Good afternoon, and thank you for joining our call today. We're here to discuss our second quarter results, which were right on plan with the financial guidance Adam provided during our last quarterly call. I'll start with bioreference laboratories. During Q2, BRL generated solid results, even as overall demand for COVID-19 testing declined. BRL continues to meet the testing needs of many significant customers who are now focused on large-scale screening in support of the transition from diagnosis to surveillance. Due to BRL's ability to provide accurate test results efficiently, it remains the test provider of choice for large public school systems, as well as all the major sports leagues who are continuing to test this year and possibly into 2022. Furthermore, testing in the travel industry is likely to continue into next year, and we are pleased to announce our agreement with Royal Caribbean Group. This, so far as we know, is the first COVID-19 testing program for the cruise industry. Due to increased awareness of the high quality of its efficient service, VRL's core business, along with its specialty testing in oncology, urology, women's health and genetics, all continue to rebound toward pre-pandemic levels. It's gratifying to see BRL convert many new COVID-19 relationships into ongoing customers for its core diagnostics offering. I'll let John speak to the great strides we're making with Scarlet Health and on-demand diagnostic service to expand digital health access to the patient's doorstep. We're enthusiastic about this initiative as we continue to position diagnostic services as a key component in the continuum of care to improve patient outcomes. As for our pharmaceutical business, we look forward to Sumatragan's upcoming PDUFA day in October, followed by determinations from the European and Japanese regulatory authorities next year. As I mentioned recently during our annual meeting, we've undertaken several initiatives to restore growth to our Rialdi franchise, including rebalancing our sales regions, more focused physician training and targeting, and updating our message to highlight the benefits of initiating treatment earlier in the disease cycle. We were pleased to have recently announced our agreement with Nicoya Therapeutics to develop and commercialize reality in mainland China, Hong Kong, Macau, and Taiwan. Infection rates for COVID-19 have recently increased throughout the country, and enrollment levels for our reality trial in COVID-19 outpatients have picked up. The primary efficacy endpoints for the trial include raising and maintaining serum total 25-hydroxyvitamin D levels within the targeted range of 50 to 100 nanograms per ml, and time to resolution of key COVID-19 symptoms. Numerous independent studies have reported an inverse correlation between vitamin D status and COVID-19 risk and severity. Reality can represent a great option for patients to quickly and safely raise 25D to sufficient levels, especially in cases of CKD and obesity. Finally, I'd like to mention that as part of our strategy to out-license certain early-stage pharmaceutical assets, we executed an agreement with Camp 4 for the development and commercialization of our antagonat technology. We continue to pursue other license opportunities like this one in order to monetize and leverage our early-stage assets. I'll now turn the call over to Steve Rubin, who will provide further commentary on our pharmaceutical business. Steve?